Results 21 to 30 of about 7,987 (192)

Clinical observation of apatinib in the treatment of metastatic colorectal cancer [PDF]

Jichu yixue yu linchuang, 2021
Objective To evaluate the efficacy and safety of apatinib in the treatment of metastatic colorectal cancer (mCRC). Methods Sixty-five patients with mCRC treated with apatinib were enrolled in this study for retrospective analysis.
CHEN Zhu, LIU Yan, GAO Li-hua, CHEN Bu-you, TANG Ai-hua, LIU Jun
doaj   +1 more source

Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Anti-Angiogenic Tyrosine Kinase Inhibitors for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Systematic Review and Single-Arm Meta-Analysis. [PDF]

Cancer Med
This single‐arm meta‐analysis (9 studies, 357 patients) shows that PD‐1/PD‐L1 inhibitors plus anti‐angiogenic TKIs yield an ORR of 48% and DCR of 83% in recurrent/metastatic nasopharyngeal carcinoma. Median PFS is 9.95 months. ICI‐naive patients benefit more (ORR 60.9% vs. 36.1%, p = 0.0028).
Hu R, Li T, Luo Z, Chen H, Qu S.
europepmc   +2 more sources

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

Low-Dose Antiangiogenic Therapy With Different Chemotherapy Backbones Among Patients With Heavily Pretreated Metastatic Breast Cancer. [PDF]

Cancer Innov
Antiangiogenic‐based regimens demonstrated superior efficacy compared to chemotherapy alone in heavily pretreated MBC patients, with manageable AEs. ABSTRACT Background The prognosis for metastatic breast cancer (MBC) remains poor, and treatment options are limited for patients with heavily pretreated disease. Although antiangiogenic agents may provide
Wang Y, Qi Y, Zeng C, Song R, Wei Y, Qian H, Ma F.   +6 more
europepmc   +2 more sources

Perioperative Camrelizumab and Apatinib for High‐Risk Resectable Hepatocellular Carcinoma: A Phase II Study [PDF]

MedComm (2020)
In this study, perioperative camrelizumab plus apatinib demonstrated promising efficacy and safety in resectable hepatocellular carcinoma (HCC) patients at high risk of recurrence, achieving a major pathological response of 46.2%. The median disease‐free survival and progression‐free survival were 24.1 months and 18.3 months, respectively.
Cui Y, Bao X, Yu G, Fang F, Li Q, Mu H, Liu C, Wu Q, Zhang W, Li H, Chen P, Liu X, Zhou H, Song T.   +13 more
europepmc   +2 more sources

Image_2_Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients.tif

, 2022
PurposeProgrammed cell death protein 1 (PD-1) inhibitor plus apatinib is reported to be a promising strategy for advanced cancers. Moreover, a PD-1 inhibitor or apatinib exerts a certain efficacy in advanced colorectal cancer (CRC), whereas their ...
Chenzhang Shi (102729), Huanlong Qin (102736), Tongyi Shen (12564868), Lichuan Liang (12564865), Dengdeng Pan (12564862), Dongliang Liu (653854)   +5 more
core   +1 more source

Advanced Hepatocellular Carcinoma With Hepatic Arterioportal Shunts: Combination Treatment of Transarterial Chemoembolization With Apatinib

Frontiers in Molecular Biosciences, 2020
Object: This study aimed to compare the efficacy and safety of transarterial chemoembolization (TACE) combining with apatinib (TACE-apatinib) and TACE-alone for patients with advanced hepatocellular carcinoma (HCC) with hepatic arterioportal shunts (APS).
Tao Sun, Tao Sun, Yanqiao Ren, Yanqiao Ren, Xuefeng Kan, Xuefeng Kan, Lei Chen, Lei Chen, Weihua Zhang, Weihua Zhang, Fan Yang, Fan Yang, Chuansheng Zheng, Chuansheng Zheng   +13 more
doaj   +1 more source

Apatinib Suppresses Gastric Cancer Stem Cells Properties by Inhibiting the Sonic Hedgehog Pathway

Frontiers in Cell and Developmental Biology, 2021
The presence of gastric cancer stem cells (GCSCs) marks the onset of gastric carcinoma. The sonic hedgehog (SHH) pathway plays a vital role in the maintenance of GCSC characteristics.
Wanshuang Cao, Yuan Li, Hongliang Sun, Chenying Yang, Jianyun Zhu, Chunfeng Xie, Xiaoting Li, Jieshu Wu, Shanshan Geng, Lu Wang, Liangfei Sun, Guozhu Geng, Hongyu Han, Caiyun Zhong   +13 more
doaj   +1 more source

Image_1_Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients.tif

, 2022
PurposeProgrammed cell death protein 1 (PD-1) inhibitor plus apatinib is reported to be a promising strategy for advanced cancers. Moreover, a PD-1 inhibitor or apatinib exerts a certain efficacy in advanced colorectal cancer (CRC), whereas their ...
Chenzhang Shi (102729), Huanlong Qin (102736), Tongyi Shen (12564868), Lichuan Liang (12564865), Dengdeng Pan (12564862), Dongliang Liu (653854)   +5 more
core   +1 more source

Apatinib Suppresses Proliferation and Induced Apoptosis of Human Breast Cancer Cell Line MDA-MB-231 Through Glycolytic Inhibition

Zhongliu Fangzhi Yanjiu, 2019
Objective To investigate the antitumor effect of apatinib on breast cancer cells in vitro and its mechanism. Methods CCK-8 assay was used to detect the inhibitory effect of apatinib on the proliferation of breast cancer cell line MDA-MB-231.
ZHANG Huazhi, LI Xiaoshuang, GUO Xiaoye, ZHAO Mingchi   +3 more
doaj   +1 more source